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Autosomal dominant hypercholesterolemia
(ADH) is an inherited disorder of cholesterol
metabolism characterized by a high concentration
of plasma low-density lipoprotein cholesterol
(LDL-C), deposition of cholesterol in tendons and
skin, and increased risk of premature coronary
heart disease (CHD). ADH is most commonly
caused by mutations in the LDL receptor (LDLR)
gene, which can lead to reduced hepatic clearance
of LDL from the blood. The estimated prevalence
of LDLR gene mutation is 1 in 500 in its heterozy-
gous form.1 To date, more than 800 mutations in
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Background/Purpose: Autosomal dominant hypercholesterolemia (ADH) is an autosomal dominant 
inherited disease characterized by an increase in low-density lipoprotein cholesterol levels and premature
coronary heart disease, which can be caused by mutations in genes encoding the low-density lipoprotein
receptor (LDLR), apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9).
There is scant information with regard to the role played by each gene in the Taiwanese ADH population,
especially the newly discovered PCSK9 gene.
Methods: We used coupling heteroduplex analysis based on a denaturing high performance liquid chro-
matography system and DNA sequencing to screen for the LDLR gene, APOB gene and PCSK9 gene in 87
ADH cases recruited from 30 unrelated Taiwanese families.
Results: We did not find any mutation-causing variant of the PCSK9 gene in our cases and thus excluded
PCSK9 as the major culprit mutation in these families. On the other hand, we identified six previously 
reported LDLR gene mutations (C107Y, D69N, R385W, W462X, G170X, V408M), two novel LDLR gene
mutations (FsG631 and splice junction mutation of intron 10), and one known mutation (R3500W) and
one novel missense mutation (T3540M) in the APOB gene that were present in 55 members from 18 ADH
families (60%). R3500W, rather than R3500Q, could be the principle mutation responsible for familial
defective apolipoprotein B in Taiwanese.
Conclusion: The results of our study reveal a characteristic mutation pattern of ADH in Taiwan, mainly in
the LDLR and APOB genes. However, PCSK9 gene mutation may not be a major cause of ADH in our study
population. [J Formos Med Assoc 2007;106(10):799–807]
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ORIGINAL ARTICLE
the LDLR gene have been reported.2 ADH can
also be caused by certain mutations in the
apolipoprotein B (APOB) gene, which encodes
for the ligand for LDLR, named familial defective
apolipoprotein B (FDB). The prevalence of FDB is
1 in 1000 in most populations.3,4 Until recently,
a third locus responsible for ADH (FH3) was
identified at 1p34.1-p32 in several large ADH kin-
dreds without mutations in the LDLR or APOB
genes.5,6 The proprotein convertase subtilisin/
kexin type 9 (PCSK9) gene, localized to the third
FH locus, has been proposed to be the third gene
with pathogenic mutations accounting for ADH.7,8
PCSK9 encodes for neural-apoptosis-regulated
convertase-1, a novel protein that may play a cru-
cial role in cholesterol homeostasis, though the
exact molecular mechanisms are still obscure.9
Although heterozygous ADH is presumed to
be a common disorder resulting in atherosclero-
sis in Asians,10 there are limited epidemiologic
and genetic data with regard to Taiwanese ADH
patients.11 The role of the PCSK9 gene in causing
ADH in Taiwanese especially needs to be clarified
so that a large-scale ADH screening program in
Taiwan can be designed in the future. To confirm
the role of the PCSK9 gene in Taiwanese with ADH
and to determine the molecular basis of ADH 
in Taiwan, we investigated the LDLR, APOB




Patients attending the Lipid Clinic at National
Taiwan University Hospital, diagnosed as having
ADH, were recruited into our study. The diagnostic
criteria of ADH included: (1) fasting plasma total
cholesterol and LDL-C levels above the 95th per-
centiles for adult Taiwanese after adjustments for
age and gender,12,13 and triglycerides < 220 mg/dL
(2.5mmol/L); (2) presence of tendon xanthomata/
xantholesma/corneal arcus or premature CHD in
the index case or a first degree relative, or a family
history of hypercholesterolemia consistent with
an autosomal dominant inheritance pattern.
Patients with secondary causes of hypercholes-
terolemia, such as hypothyroidism, renal or he-
patic disease, and those with clinically suspected
familial combined hyperlipidemia were excluded.
Family members of the index ADH case were in-
vited to participate in the screening program and
those who met the diagnostic criteria for ADH
were also recruited.
Control subjects were healthy adult volunteers
without known underlying dyslipidemia, cardio-
vascular disease, active inflammation or malig-
nancy. We collected blood samples from 50 control
subjects for genetic analysis (described later).
Lipid measurements
Blood samples from fasting patients without
concurrent lipid-lowering therapy were obtained
for measurements. The concentration of plasma
total cholesterol, high-density lipoprotein choles-
terol, and triglycerides were determined with com-
mercially available kits (Boehringer Mannheim).




Genomic DNA was isolated from EDTA whole
blood with the Puregene DNA Isolation Kit
(Gentra Systems Inc., Minneapolis, MN, USA)
according to the manufacturer’s instructions.
Polymerase chain reaction
Polymerase chain reaction (PCR) amplification
of the LDLR gene (including the promoter, 18
coding exons and flanking intron regions), APOB
gene (exon 26 of the APOB gene containing
codons 3473–3561, which harbors two known
pathogenic mutation sites, R3500Q and R3500W,
as well as four other known genetic variants of
potential pathogenic importance15–18), and PCSK9
gene (the 12 exons and flanking intron regions)
were performed with the primers as shown in
Table 1. Each PCR mixture, with a total volume of
25mL, contained 50ng of genomic DNA, 0.12mM
of each primer, 100 mM dNTPs, 0.5 units of
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AmpliTaq GoldTM enzyme (PE Applied Biosystems,
Foster City, CA, USA), and 2.5 mL of GeneAmp
10X buffer II (10 mM Tris-HCl; pH, 8.3; 50 mM
KCl), in 2 mM MgCl2 as provided by the manu-
facturer. Amplification was performed in a multi-
block system thermocycler (ThermoHybaid,
Ashford, UK). PCR amplification was performed
with an initial denaturation step at 95°C for 10
minutes, followed by 35 cycles consisting of 
denaturation at 94°C for 30 seconds, annealing
at 55–57°C for 60 seconds (specific annealing
temperatures for each PCR product are listed in
Table 1), extension at 72°C for 30 seconds, and
then a final extension step at 72°C for 10 minutes.
ADH in Taiwanese
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Table 1. Primers used for polymerase chain reaction of the LDLR gene, 26th exon of the APOB gene, and the
PCSK9 gene, and denaturing high performance liquid chromatography (DHPLC) temperatures
Forward primer Reverse primer
Annealing DHPLC 
temperature (°C) temperature (°C)
LDLR
Exon 1 5tttccagctaggacacagca3 5ctcaccctgtggagacttgg3 57 60
Exon 2 5tgggttccttctttgtgtcc3 5tggcgagaccctgtctctat3 56 58
Exon 3 5tcttgaacccctgacctcac3 5caggaccccgtagagacaaa3 57 62
Exon 4-1 5gacttcacacggtgatggtg3 5ccccttggaacacgtaaaga3 57 65
Exon 4-2 5aagtgcatctctcggcagtt3 5ccagggacaggtgataggac3 57 65
Exon 5 5caggctggtcttgaactcct3 5agcagcaaggcacagagaat3 55 62.5
Exon 6 5ctcccaaagtgctgggatta3 5ttcccaaaaccctacagcac3 57 62
Exon 7 5cagctacttgggaggctgag3 5gttttccatgcaggtggaat3 57 63.5
Exon 8 5cttcgaaggtgtgggttttg3 5gcaagcccaagtcctaacag3 57 62
Exon 9 5gaggcactcttggttccatc3 5tctctgctgatgacggtgtc3 57 64
Exon 10 5ggtctgacctgtcccagaga3 5cttcctgctccctccattc3 57 62
Exon 11 5aagccacatttggagtttgg3 5aaaccttcagggagcagctt3 57 62
Exon 12 5ccaggtgcttttctgctagg3 5caaccagttttctgcgttca3 57 61.5
Exon 13 5cgagattgggccactgtact3 5tccacaaggaggtttcaagg3 57 62
Exon 14 5caagaggtaagggtgggtca3 5gagcagagagaggctcagga3 57 64
Exon 15 5cctcccaaggtcatttgaga3 5gtcagcaagggagtgaggac3 57 64
Exon 16 5tgtggcctctcacagacttg3 5ttccctgtccaggagaaaaa3 57 63
Exon 17 5tatggtacgatgcccgtgtt3 5cgcacagaagcattcaccta3 57 61
Exon 18 5cggtgggaagtgactgaatc3 5ggcaatgctttggtcttctc3 57 62
Prom 5cagctcttcaccggagaccc3 5acctgctgtgtcctagctgg3 57 61.5
APOB
Exon 26 5tgtcaagggttcggttcttt3 5gggtggctttgcttgtatgt3 56 58.5
PCSK9
Exon 1 5cttcagctcctgcacagtc3 5gaaactgaggcccgagag3 57 62
Exon 2 5aggggtgagataaagtacacct3 5aagcacagtccccagtgtat3 56 60.5
Exon 3 5gggacaggtttgatcaggta3 5tcagtggaggtgctgagtc3 57 61
Exon 4 5tgtgctctgtagtttgtgtgtg3 5atgctctggggtggcagt3 57 59
Exon 5 5ctgtactcctgggttgcac3 5cacagcattcttggttagga3 57 64
Exon 6 5ccatcactctgtgcctgtaa3 5ggaacgtgccacaagaag3 57 62
Exon 7 5aaggcctgagtctgcctct3 5ccatcaggcctacttcatct3 55 60
Exon 8 5gtgtatgtgtgtgcgtgtgt3 5agggagaagggagagactgt3 57 63.5
Exon 9 5cctcctctctcctaccatga3 5acagaagagctggagtctgg3 57 61
Exon 10 5atgagggtgcttgagttgat3 5gatcacacttgtgaggacca3 57 62
Exon 11 5agctcttgcctcagacctta3 5ggcacaaactgacacagaaa3 56 63
Exon 12 5gagggagaaatgaagtgtgg3 5agtcggaaccattttaaagc3 57 62
Denaturing high performance liquid
chromatography analysis
Mutation analysis was performed on a Transge-
nomic Wave Nucleic Acid Fragment Analysis
System (Transgenomic Inc., San Jose, CA, USA).
Denaturing high performance liquid chromatog-
raphy (DHPLC) was carried out on an automated
HPLC instrument equipped with a DNASep col-
umn (Transgenomic Inc.). DHPLC-grade acetoni-
trile (9017-03; JT Baker, Phillipsburg, NJ, USA)
and triethylammonium acetate (TEAA; Transge-
nomic Inc., Crewe, UK) were used to constitute
the mobile phase. The mobile phases comprised
0.05% acetonitrile in 0.1 M TEAA (eluent A) and
25% acetonitrile in 0.1 M TEAA (eluent B). For
heteroduplex detection of crude PCR products,
they were subjected to an additional 3-minute
95°C denaturing step followed by gradual rean-
nealing from 95°C to 65°C over a period of 30
minutes prior to analysis, and were eluted at a flow
rate of 0.9 mL/min. The start- and end-points of
the gradient obtained by mixing eluents A and B
and the temperature required for successful reso-
lution of heteroduplex molecules, were deduced
from the WAVEmaker system control software
version 4.1.42 (Transgenomic Inc.). Eight micro-
liters of PCR product were injected for analysis in
each run. The DHPLC temperatures for each PCR
product are listed in Table 1. Heterozygous pro-
files were identified by visual inspection of the
chromatograms on the basis of the appearance
of additional earlier eluting peaks. Corresponding
homozygous profiles are shown as only one peak.
Direct sequencing analysis
The PCR products from index cases of ADH who
showed abnormal DHPLC heteroduplex patterns
compared with controls were sequenced. Ampli-
cons were purified by solid-phase extraction and
bidirectionally sequenced with the PE Applied
Biosystems Taq DyeDeoxy terminator cycle se-
quencing kit according to the manufacturer’s 
instructions. Sequencing reactions were separated
on a PE Applied Biosystems 373A/3100 sequencer.
Mutation was defined as base alterations that
were not found in volunteer samples, while sin-
gle nucleotide polymorphisms (SNPs) were de-
fined as base alterations that were found in control
samples (50 control blood samples were screened
utilizing DHPLC for mutation/SNP confirmation).
Results
Clinical characteristics
Thirty unrelated ADH families, with a total of 87
members, were recruited. The demographic data,
clinical features and lipid profiles of the subjects
are shown in Table 2. Eighteen (20.7%) of the ADH
cases had a history of CHD. Pretreatment plasma
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Table 2. Clinical and biochemical characteristics of the autosomal dominant hypercholesterolemia cases*
All (N = 87) Men (N = 46) Women (N = 41)
Age (yr) 42.3 ± 14.3 (14–70) 40.4 ± 14.0 (14–56) 44.2 ± 15.0 (18–70)
Hypertension† 18 (21) 12 (26) 6 (15)
Total cholesterol (mg/dL)‡ 316.0 ± 68.5 (268–500) 312.0 ± 79.3 (268–500) 320.8 ± 59.8 (278–475)
LDL-C (mg/dL)‡ 220.6 ± 52.6 (172–400) 208.4 ± 17.6 (172–400) 231.4 ± 70.5 (174–389)
HDL-C (mg/dL)‡ 48.3 ± 11.6 (29–73) 38.9 ± 5.6 (29–47) 55.6 ± 9.5 (42–73)
Triglyceride (mg/dL)‡ 108.8 ± 52.2 (18–219) 118.2 ± 36.7 (77–186) 99.3 ± 65.1 (18–219)
CHD history 18 (20.7) 12 (26.1) 6 (14.6)
Presence of tendon 14 (16.1) 9 (19.5) 5 (12.2)
xanthomata/corneal 
arcus/xantholesma
*Data are presented as mean ± standard deviation (range) or n (%); †none of the included subjects had diabetes mellitus; ‡to convert
total cholesterol, LDL-C and HDL-C in mg/dL to mmol/L, divide by 38.7, and to convert triglyceride in mg/dL to mmol/L, divide by
88.6. LDL-C = low-density lipoprotein cholesterol; HDL-C = high-density lipoprotein cholesterol; CHD = coronary heart disease.
total cholesterol ranged from 268 to 500 mg/dL
(6.9–12.9 mmol/L), and LDL-C ranged from 172
to 400 mg/dL (4.5–10.3 mmol/L).
LDLR gene variants
Using DHPLC analysis, we discovered a total of
14 nucleotide changes in the LDLR gene. Direct
DNA sequencing of the amplicons confirmed
eight mutations and six polymorphisms (Table
33,19–24 and Table 425–28). The discovered LDLR
gene mutations included four missense mutations
(C107Y, D69N, R385W, V408M), two nonsense
mutations (G170X, W462X), one novel deletion
(c.1954_1955 del AT) leading to frameshift
(FsG631), and one novel splice site mutation at
intron 10 (c.1586 + 5G > C). Both of the newly-
discovered LDLR gene mutations were shown to
co-segregate well with the clinical ADH phenotype
and were not found in control subjects. Among
the identified LDLR gene polymorphisms, two
have been reported previously (C > T at 1617 and
C > T at 81) and two are novel (A > G at 1415 and
C > T at 2558). The number of families carrying
these polymorphisms is listed in Table 4.25–28
APOB gene variants
Four of our study families were discovered to carry
mutations in the APOB gene. Three of them were
heterozygous carriers of FDB causing missense
mutation of R3500W, and the other one carried
a novel missense mutation of T3540M. Missense
mutation of R3500Q and the other four APOB
genetic variants of pathogenic importance in hy-
percholesterolemia were not identified in our ADH
families.15–18 The T3540M mutation was found to
co-segregate with the hypercholesterolemia trait
in this family.
PCSK9 gene variants
PCSK9 mutations were not detected in any of the
30 ADH probands. DHPLC and sequence analysis
of the PCSK9 gene revealed only three previously
described polymorphisms (Table 5).29,30
ADH in Taiwanese
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Table 3. Mutations identified in the LDLR, APOB and PCSK9 genes among the autosomal dominant
hypercholesterolemia families
Family* Exon Nucleotide change Amino acid change Mutation class† Reference
LDLR gene
F1, F12 4 CT571 G170X Class 1 Chinese [19]
F3, F13 3 GA268 D69N Class 2B UK [20]; Chinese [19]
F4, F15 9 GA1285 V408M Class 5 South African [21]
F5 9 CT1216 R385W Class 5 Israel [22]
F7 4 GA383 C107Y Class 3 French [23]
F10 10 GA1448 W462X Class 2B/5 Chinese; Austrian [24]
F16, F28, F30 13 delAT1954 FsG631 Class 5 Novel
F20, F29 Intron 10 GC1586 + 5 Skipping of exon 10 Class 2B/5 Novel
APOB gene
F23, F25, F27 26 CT10707 R3500W Gaffney et al [3]
T1 26 CT10828 T3540M Novel
*The numbering system for autosomal dominant hypercholesterolemia families consisted of a capitalized F or T, which denotes family,
and a following digit, which indicates the number assigned to the autosomal dominant hypercholesterolemia family; †mutation class
was assigned according to the functional domains described in the references.
Table 4. Polymorphisms identified in the LDLR
gene among 30 Taiwanese autosomal
dominant hypercholesterolemia probands
Exon
Nucleotide Families carrying 
Reference
change the SNP, n
2 CT81 1 25
10 GA1413 1 26
10 AG1415 3 Novel
11 CT1617 4 27
13 CT1959 1 28
16 CT2258 1 Novel
SNP = single nucleotide polymorphism.
Discussion
We identified eight mutations in the LDLR gene
and two mutations in the APOB gene among 55
members from 18 out of 30 ADH families in this
study. None of our cases were found to harbor
mutations in the PCSK9 gene. All the mutations
we identified were confirmed in at least two of
the recruited ADH families. This is the first com-
prehensive mutation study of the three known
genes causing ADH in Taiwanese.
Among the identified LDLR gene mutations,
only three (D69N, W462X, G170X) have previ-
ously been reported in Chinese.19,24 The novel
deletion of AT at nucleotide 1954–1955 results in
a frameshift from codon 631 of the EGF precursor
homology region. This novel deletion was identi-
fied in three of our ADH families (F16, F28, F30),
in which affected members all had markedly ele-
vated plasma LDL-C levels. Another novel muta-
tion was identified at the splice site c.1586 + 5G > C
of the LDLR gene in families F20 and F29, which
may result in an erroneous skipping of exon 10,
since the G nucleotide, a 5 splice donor, is essen-
tial for proper splicing.31 The co-segregation of
mutations and hypercholesterolemia in ADH
probands and their family members implied that
the newly identified genetic variants were pre-
sumably responsible for ADH. However, further
expression studies are needed to confirm the
functional role of the two novel LDLR gene
mutations. Interestingly, these two recurrent
novel mutations accounted for 17% (5 of 30) of
the recruited ADH families, which may suggest
the presence of characteristic common mutations
due to a founder effect in the Taiwanese ADH
population. It is necessary to screen a larger num-
ber of ADH subjects to confirm the hypothesis in
the future.
Among the 30 recruited ADH families, three
were found to have the R3500W mutation in the
APOB gene. Interestingly, the prevalent R3500Q
mutation in Caucasians was not identified in our
ADH population. This finding is consistent with
one previous study that evaluated the prevalence
of FDB among hypercholesterolemic subjects in
Taiwan,32 in which the R3500W allele is far more
prevalent than the R3500Q one (2.4% vs. 0.3%)
among those with moderate hypercholesterolemia.
In family T1, we identified a c.10828C > T nu-
cleotide change in the APOB gene, which results
in a substitution of threonine to methionine at
codon 3540 (T3540M). This novel missense mu-
tation is, to our knowledge, the seventh APOB
genetic variant to be associated with hypercho-
lesterolemia. However, even some well-known
APOB mutations (such as R3531C) are not con-
sistently found to be related to hypercholes-
terolemia.33 The pathogenic role and clinical
significance of the T3540M mutation require 
further investigation.
Unexpectedly, we failed to find mutation-
causing PCSK9 gene variants other than polymor-
phism in our study subjects. PCSK9 gene mutations
were found in 12.5% of the families without
LDLR/APOB mutation in the original French 
series.7 However, in a recent Danish study,34 the
PCSK9 gene was excluded to be responsible for
ADH in 20 LDLR/APOB mutation-negative fami-
lies. The results suggest that the genetic variants
of PCSK9 may not play a significant role in caus-
ing ADH in certain ethnic groups. Or at the very
least, the prevalence of ADH families carrying 
a PCSK9 mutation could be very low among these
populations.
Tendon xanthomata, corneal arcus or xan-
tholesma was present in 16.1% (14 of 87) of our
study subjects (Table 2). Several of these cases
were found to have mutations in the LDLR gene
(three had delAT1954, two had GC 1586 + 5,
four had R385W, W462X, V408M and C107Y).
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Table 5. Polymorphisms identified in the PCSK9
gene among 30 Taiwanese autosomal
dominant hypercholesterolemia probands
Exon/ Nucleotide Families carrying
Reference
Intron change the SNP, n
5 CT658 –7 1 29
9 GA1624 1 30
10 AG1680 +64 1 29
SNP = single nucleotide polymorphism.
None of these cases were associated with APOB
gene mutation. Although cases with such patho-
gnomonic physical findings were more often
found to have a mutation in the LDLR gene
(64.3%, 9 of 14), there were still five cases 
without an identifiable mutation in the LDLR,
APOB or PCSK9 genes.
We failed to identify mutations responsible for
ADH among 35 of our cases (from 12 different
families), making a mutation detection rate of
60%, while the mutation detection rate was 41% in
another report on Taiwanese familial hypercho-
lesterolemia patients (without taking the PCSK9
gene into consideration).11 The mutation detection
rate in Taiwanese ADH patients was relatively low
in comparison with previous studies.19 One rea-
son for the result is probably the technical prob-
lems. The sensitivity and specificity of DHPLC
are approximately 95%, irrespective of sequence
variations, except for some high-melting regions
surrounded by lower-melting sequences. The op-
timal size of an amplicon varies between 150 bp
and 700 bp, depending on GC content. Any dele-
tion beyond that size will not be detected by
DHPLC, and alternative methods such as long
PCR or Southern blotting would be required to
exclude large deletions or rearrangements. We
could have missed some mutations like these in
our analyses, if they had occurred in the LDLR
and PCSK9 genes.
Another reason for this result could be the ex-
istence of additional monogenic or polygenic
causes responsible for the ADH phenotype due
to ethnic differences. For example, despite an 
extensive search for mutations in the LDLR and
APOB genes, the underlying genetic changes still
could not be identified in a significant portion of
ADH patients in the United Kingdom20 and
Malaysia.35 The molecular basis of the ethnic dif-
ferences will require further effort to determine.
A third reason could be due to the relatively less
strict lipid criteria for ADH. Take the US MEDPED
(Make Early Diagnosis to Prevent Early Death)
program36 cut points for ADH diagnosis as an ex-
ample: adult patients older than 30 years need to
have a serum cholesterol level of 290–340 mg/dL
(7.5–9.3 mmol/L) to be diagnosed as an index
case of ADH. However, the cut point for total
cholesterol used in this study was 260 mg/dL
(6.8 mmol/L) for Taiwanese of the same age.
Although the lower absolute levels of cholesterol
and LDL-C in Taiwanese could be due to a differ-
ent diet and lifestyle from that in Western coun-
tries and would not affect the diagnostic power
of the percentile criteria, we cannot exclude the
possibility that some non-ADH probands would
still be included due to frank hypercholes-
terolemia and an ambiguous family history.
In conclusion, the genetic background of
Taiwanese ADH patients is highly heterogeneous,
consisting of a variety of different mutations in
the LDLR and APOB genes. However, there may
be some common mutations responsible for a
significant portion of the ADH population in
Taiwan. The mutations of the PCSK9 gene seem
not to play a significant role in causing ADH in
Taiwanese. These observations reflect the hetero-
geneous ethnic origins of Taiwanese and a char-
acteristic mutation pattern that is different from
that in other countries. A larger screening program
is required to clarify the epidemiologic features
of ADH in Taiwan. In vitro expression study is also
needed to confirm the functional implications of
the newly identified mutations in ADH patients.
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